KPV

KPV, or Lysine-Proline-Valine, is a tripeptide fragment derived from alpha-melanocyte-stimulating hormone (α-MSH). As a fragment, it represents a smaller, more targeted portion of the larger α-MSH molecule, potentially offering a more focused biological activity. KPV is not FDA-approved for any specific therapeutic use and is currently unregulated, meaning its production and distribution are not subject to stringent FDA oversight. This places the onus on consumers to vet suppliers and ensure product quality through independent testing.

The mechanism of action for KPV is primarily attributed to its anti-inflammatory properties. Research suggests that KPV interacts with the innate immune system, specifically targeting the NF-κB pathway, a key regulator of inflammation. By inhibiting NF-κB activation, KPV can potentially reduce the production of pro-inflammatory cytokines and chemokines, thereby mitigating inflammatory responses. Some studies also indicate a potential interaction with the melanocortin 1 receptor (MC1R), although this is less well-defined than its impact on NF-κB.

The research landscape surrounding KPV is relatively robust, with 185 research papers and 50 clinical trials listed. However, it's important to note the phase and nature of these trials. For example, the "Pre-emptive Kidney Transplantation Quality of Life" trial (n=390) and "The Impact of Selected Factors on the Cardiovascular System in Chronic Kidney Disease" trial (n=252) are listed as Phase None, suggesting observational studies rather than interventional trials specifically testing KPV. Similarly, the "NIraparib and Quality of LifE" study (n=141) is a Phase 4 trial, indicating it focuses on post-market surveillance of a different drug, Niraparib, and its impact on quality of life, potentially including amino acid profiles. The "Dosing Study of Amino Acids in Seriously Ill Patients" (n=16) was terminated, highlighting the challenges and complexities of clinical research.

Several key research papers shed light on KPV's potential applications. A review published in the *International Journal of Medical Sciences* with 192 citations explores the role of tripeptides, including KPV, in wound healing and skin regeneration. Other papers investigate its role in inflammatory conditions. For instance, a paper in *Science Advances* (75 citations) explores inflammation-triggered self-immolative conjugates for oral peptide delivery, aiming to overcome gastrointestinal barriers. A study in *Cell Death & Differentiation* (71 citations) examines the disruption of NLRP3 autophagic degradation in melanocytes and its contribution to vitiligo development. Furthermore, a paper in *Frontiers in Pharmacology* (58 citations) discusses a PepT1-targeted nanodrug based on KPV for treating colitis. These diverse research areas highlight the broad interest in KPV's potential therapeutic applications.

The safety profile of KPV appears favorable based on available data. The FDA adverse event database shows zero reported events associated with KPV. However, the lack of FDA regulation means that adverse events may be underreported, and the long-term safety of KPV is not fully established. The "Safety score" of 80.0 reflects this uncertainty.

KPV is reportedly used by individuals seeking support for gut health, immune function, and wound healing. Given its anti-inflammatory properties, it is also explored by those with inflammatory conditions. However, without FDA approval, these uses are based on anecdotal evidence and preliminary research, not on established clinical efficacy.

The regulatory outlook for KPV remains uncertain, and further research is needed to fully elucidate its mechanisms of action, efficacy, and long-term safety before any potential regulatory changes or approvals could occur.